January 6, 2017


Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome

Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced entering into an exclusive worldwide licensing agreement with Duke University to develop RVT-802, a tissue-based therapy for the treatment of complete DiGeorge Syndrome (cDGS), a rare and fatal congenital immunodeficiency disease. In the absence of treatment, children born with cDGS typically succumb to infections within the first two years of life due to their severe immunodeficiency. RVT-802 is a biologic therapy for complete DiGeorge Syndrome, a fatal pediatric disease affecting roughly 10-20 children per year in the United States.

To read full article, click here.